Clin Mol Hepatol.
2013 Mar;19(1):82-86. 10.3350/cmh.2013.19.1.82.
Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B
- Affiliations
-
- 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. gihankhys@yuhs.ac
- 2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
- 3Liver Cirrhosis Clinical Research Center, Seoul, Korea.
- 4Brain Korea 21 Project of Medical Science, Seoul, Korea.
- 5Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.
- KMID: 1493579
- DOI: http://doi.org/10.3350/cmh.2013.19.1.82
Abstract
- Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV). Clinical trials have shown that telbivudine has a more potent and sustained antiviral activity with a lower frequency of viral resistance than lamivudine. Although there are several reports concerning the safety profile of telbivudine, most adverse events are described as mild and transient in nature. Here we report two cases of telbivudine-induced myopathy in patients with chronic hepatitis B who were siblings.
Keyword
MeSH Terms
-
Adult
Antiviral Agents/adverse effects/*therapeutic use
Creatine Kinase/blood
Electromyography
Hepatitis B, Chronic/*drug therapy/metabolism/pathology
Humans
Male
Muscle, Skeletal/pathology
Muscular Diseases/etiology
Siblings
Thymidine/adverse effects/*analogs & derivatives/therapeutic use
Antiviral Agents
Thymidine
Creatine Kinase
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors
- Mitochondrial myopathies caused by prolonged use of telbivudine
- Antiviral Therapy for Chronic Hepatitis B
- Efficacy of Entecavir Switching Therapy in Chronic Hepatitis B Patients with Clevudine-induced Myopathy
- 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
